Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118


Biochemical and genetic association of plasma apolipoprotein A-II levels with familial combined hyperlipidemia.

Allayee H, Castellani LW, Cantor RM, de Bruin TW, Lusis AJ.

Circ Res. 2003 Jun 13;92(11):1262-7. Epub 2003 May 8.


Expression of human apolipoprotein A-II in apolipoprotein E-deficient mice induces features of familial combined hyperlipidemia.

Escolà-Gil JC, Julve J, Marzal-Casacuberta A, Ordóñez-Llanos J, González-Sastre F, Blanco-Vaca F.

J Lipid Res. 2000 Aug;41(8):1328-38.


Apolipoprotein A-II, genetic variation on chromosome 1q21-q24, and disease susceptibility.

Martín-Campos JM, Escolà-Gil JC, Ribas V, Blanco-Vaca F.

Curr Opin Lipidol. 2004 Jun;15(3):247-53. Review.


Contribution of the hepatic lipase gene to the atherogenic lipoprotein phenotype in familial combined hyperlipidemia.

Allayee H, Dominguez KM, Aouizerat BE, Krauss RM, Rotter JI, Lu J, Cantor RM, de Bruin TW, Lusis AJ.

J Lipid Res. 2000 Feb;41(2):245-52.


The Gln223Arg polymorphism in the leptin receptor is associated with familial combined hyperlipidemia.

van der Vleuten GM, Kluijtmans LA, Hijmans A, Blom HJ, Stalenhoef AF, de Graaf J.

Int J Obes (Lond). 2006 Jun;30(6):892-8.


Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study.

Veerkamp MJ, de Graaf J, Bredie SJ, Hendriks JC, Demacker PN, Stalenhoef AF.

Arterioscler Thromb Vasc Biol. 2002 Feb 1;22(2):274-82.


Segregation analysis of plasma apolipoprotein B levels in familial combined hyperlipidemia.

Bredie SJ, van Drongelen J, Kiemeney LA, Demacker PN, Beaty TH, Stalenhoef AF.

Arterioscler Thromb Vasc Biol. 1997 May;17(5):834-40.


Apolipoprotein A-I/C-III/A-IV gene cluster in familial combined hyperlipidemia: effects on LDL-cholesterol and apolipoproteins B and C-III.

Dallinga-Thie GM, Bu XD, van Linde-Sibenius Trip M, Rotter JI, Lusis AJ, de Bruin TW.

J Lipid Res. 1996 Jan;37(1):136-47.


Association of plasma lipids and apolipoproteins with the insulin response element in the apoC-III promoter region in familial combined hyperlipidemia.

Groenendijk M, Cantor RM, Blom NH, Rotter JI, de Bruin TW, Dallinga-Thie GM.

J Lipid Res. 1999 Jun;40(6):1036-44.


Role of insulin resistance in familial combined hyperlipidemia.

Veerkamp MJ, de Graaf J, Stalenhoef AF.

Arterioscler Thromb Vasc Biol. 2005 May;25(5):1026-31. Epub 2005 Feb 24.


Plasma lipoproteins, apolipoproteins, and triglyceride metabolism in familial hypertriglyceridemia.

Stalenhoef AF, Demacker PN, Lutterman JA, van 't Laar A.

Arteriosclerosis. 1986 Jul-Aug;6(4):387-94.


Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein.

Blanco-Vaca F, Escolà-Gil JC, Martín-Campos JM, Julve J.

J Lipid Res. 2001 Nov;42(11):1727-39. Review.


Decreased adiponectin levels in familial combined hyperlipidemia patients contribute to the atherogenic lipid profile.

van der Vleuten GM, van Tits LJ, den Heijer M, Lemmers H, Stalenhoef AF, de Graaf J.

J Lipid Res. 2005 Nov;46(11):2398-404. Epub 2005 Aug 16.


Complex genetic contribution of the Apo AI-CIII-AIV gene cluster to familial combined hyperlipidemia. Identification of different susceptibility haplotypes.

Dallinga-Thie GM, van Linde-Sibenius Trip M, Rotter JI, Cantor RM, Bu X, Lusis AJ, de Bruin TW.

J Clin Invest. 1997 Mar 1;99(5):953-61.


A Caucasian male with very low blood cholesterol and low apoA-II without evidence of atherosclerosis.

Park SH, Kim JR, Park JE, Cho KH.

Eur J Clin Invest. 2007 Apr;37(4):249-56.


Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.

Ribas V, Sánchez-Quesada JL, Antón R, Camacho M, Julve J, Escolà-Gil JC, Vila L, Ordóñez-Llanos J, Blanco-Vaca F.

Circ Res. 2004 Oct 15;95(8):789-97. Epub 2004 Sep 23.

Supplemental Content

Support Center